Apogee Therapeutics Finalizes $402.5M Public Offering at $70.00/Share

summarizeSummary

Apogee Therapeutics finalized its public offering, selling 5.75 million shares at $70.00 per share, raising approximately $377.4 million in net proceeds to fund operations.

check_boxKey Events

• Public Offering Finalized

  Apogee Therapeutics entered into an underwriting agreement to sell 5,000,000 shares of common stock.

• Over-Allotment Option Fully Exercised

  The underwriters fully exercised their option to purchase an additional 750,000 shares, bringing the total to 5,750,000 shares.

• Offering Price and Proceeds

  The shares were sold at a public offering price of $70.00 per share, generating approximately $377.4 million in net proceeds.

• Expected Closing Date

  The offering is expected to close on March 26, 2026.

auto_awesomeAnalysis

This 8-K filing finalizes the terms and pricing of the previously announced public offering, following positive Phase 2 clinical trial data. Apogee Therapeutics sold 5.75 million shares, including the full exercise of the underwriters' over-allotment option, at $70.00 per share. While the offering is dilutive and priced at a discount to the current market price, it successfully raises approximately $377.4 million in net proceeds. For a life sciences company, securing substantial capital is crucial for advancing its clinical pipeline and extending its operational runway, significantly strengthening its balance sheet.